Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Thorac Cancer. 2020 Dec;11(12):3641-3644. doi: 10.1111/1759-7714.13687. Epub 2020 Oct 19.
Bevacizumab is the first antiangiogenetic monoclonal antibody, combined with platinum-based double agent chemotherapy, which has been reported to improve the objective response rate (ORR) and progression-free survival (PFS) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC), and to improve overall survival (OS) in patients when combined with carboplatin and paclitaxel. However, serious adverse effects have been reported to be associated with bevacizumab therapy. In this multicenter prospective cohort study of advanced lung adenocarcinoma patients with stable disease after two cycles of platinum-based double agent chemotherapy, we will compare the ORR between the group who continued with their original chemotherapy regimen and the group in which bevacizumab was added to the original regimen. It is expected that there will be an ORR improvement of 20% in patients in the bevacizumab group plus chemotherapy, compared with those in the original chemotherapy group. This study has been registered as Clinical Trial NCT03240549.
贝伐珠单抗是首个抗血管生成的单克隆抗体，与铂类双药化疗联合应用，已被报道可提高晚期非鳞状非小细胞肺癌（NSCLC）患者的客观缓解率（ORR）和无进展生存期（PFS），并与卡铂和紫杉醇联合应用时可提高患者的总生存期（OS）。然而，有报道称贝伐珠单抗治疗与严重不良反应相关。在这项针对铂类双药化疗后疾病稳定的晚期肺腺癌患者的多中心前瞻性队列研究中，我们将比较继续使用原化疗方案组和在原方案中添加贝伐珠单抗组的 ORR。预计贝伐珠单抗联合化疗组的患者 ORR 将提高 20%，与原化疗组相比。本研究已在 ClinicalTrials.gov 上注册，编号为 NCT03240549。
